01
Coverage over selectivity
Cover every peptide users search for, regardless of evidence strength.
A page that says 'high risk, no human RCTs, here is why we know' is more useful than no page at all. Catalog gaps are bugs, not features. Thin-evidence peptides like BPC-157, dihexa, melanotan-II, NMN derivatives and semax variants get pages that frame them honestly, not omitted.
Example
If you searched 'is dihexa safe?' and we had no page, you would end up on a vendor's homepage instead. We would rather be the page that tells you the cancer-pathway concern up front.
02
Risk framing IS the product
When evidence is weak, we make the gap legible. Plain language. Not buried.
Risk is content, not legal cover. Every peptide page surfaces its risk band explicitly. HIGH RISK means no human RCTs plus regulatory red flags plus community-reported adverse events. MEDIUM RISK means thin clinical data, plausible mechanism, tolerable observational safety. LOW RISK means Phase 3 RCTs, multi-region approval and long real-world safety.
Example
Melanotan-II is HIGH RISK (melanoma cluster reports). Tirzepatide is LOW RISK (Phase 3, multi-region approval). Both get a page. Both surface the band on top.
03
Neutral on regulators
FDA's position is one signal, not the only one.
We always present FDA position alongside TGA (Australia), EMA (EU), MHRA (UK), MOH-X (Singapore, Bali, Vietnam, Thailand and others), plus community-reported off-label clinical practice. 'Not FDA approved' is incomplete on its own. We report what other agencies say AND why they differ. We acknowledge the pharma-lobby critique without endorsing it. Approval status is a fact about a regulator's decision, not a normative judgment about the molecule.
Example
Tirzepatide compounding is restricted by FDA but legal under HSA Singapore and TGA Australia for specific patient populations. We say all three things on the page.
04
We don't gatekeep
Some users have legitimate reasons not to wait for FDA approval. Some prefer regulator-led caution. Both are valid.
We don't tell you whether to wait. We give you the data and you decide. We don't filter out information that paternalism-leaning sites would hide. Consent and transparency are the design, not gatekeeping. The matchmaker shows the full range of legal options for your region; you decide.
Example
A vendor flagged 'Documented Risk' surfaces to users with mandatory disclosure. They are not hidden. You see the risk and the source, and you choose.
05
Run by AI, improved by data
Panya is built and operated by AI agents. We don't hide that. We say it.
Agents in the loop: Santora (vendor discovery + scoring), vendor-match (Opus 4.5), content-cmo (social drafts), forum-finder (forum question discovery + draft replies), Reply-Autopilot (inbound triage), Retro Agent (weekly self-review) and a Haiku 4.5 supervisor that quality-gates every agent output. The catalog updates as data flows. New literature triggers a refresh and a revised risk band. User behavior surfaces coverage gaps. Community signals raise new vendors and new risks. User corrections sent to partner@panya.health land within the same week.
Example
Every page can show 'last reviewed' date. Corrections are versioned, not silent. Continuous improvement is the product, not a one-time launch event.